Effect of statins on survival in patients undergoing dialysis access for end-stage renal disease
Autor: | Basso Parente, Alessandra Manzone, Massimo Lenti, Paola De Rango, Gioele Simonte, Beatrice Fiorucci, Luca Farchioni, Selena Pelliccia, Enrico Cieri |
---|---|
Rok vydání: | 2016 |
Předmět: |
Aged
Aged 80 and over Chi-Square Distribution Female Graft Occlusion Vascular Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Kaplan-Meier Estimate Kidney Failure Chronic Male Middle Aged Odds Ratio Proportional Hazards Models Protective Factors Retrospective Studies Risk Assessment Risk Factors Time Factors Treatment Outcome Vascular Patency Renal Dialysis Surgery Cardiology and Cardiovascular Medicine 030204 cardiovascular system & hematology Graft Occlusion Kidney Failure 0302 clinical medicine Hyperlipidemia 80 and over Clinical endpoint 030212 general & internal medicine Chronic medicine.medical_specialty Statin medicine.drug_class End stage renal disease 03 medical and health sciences Vascular Internal medicine Diabetes mellitus medicine cardiovascular diseases Proportional hazards model business.industry nutritional and metabolic diseases Odds ratio medicine.disease business Kidney disease |
Zdroj: | Seminars in Vascular Surgery. 29:198-205 |
ISSN: | 0895-7967 |
Popis: | The benefit of statin therapy in patients with advanced chronic kidney disease remains uncertain. Randomized trials have questioned the efficacy of the drug in improving outcomes for on-dialysis populations, and many patients with end-stage renal disease are not currently taking statins. This study aimed to investigate the impact of statin use on survival of patients with vascular access performed at a vascular center for chronic dialysis. Consecutive end-stage renal disease patients admitted for vascular access surgery in 2006 to 2013 were reviewed. Information on therapy was retrieved and patients on statins were compared to those who were not on statins. Primary endpoint was 5-year survival. Independent predictors of mortality were assessed with Cox regression analysis adjusting for covariates (ie, age, sex, hyperlipidemia, hypertension, cardiac disease, cerebrovascular disease, chronic obstructive pulmonary disease, obesity, diabetes, and statins). Three hundred fifty-nine patients (230 males; mean age 68.9 ± 13.7 years) receiving 554 vascular accesses were analyzed: 127 (35.4%) were on statins. Use of statins was more frequent in patients with hypertension (89.8% v 81%; P = .034), hyperlipidemia (52.4% v 6.2%; P < .0001), coronary disease (54.1% v 42.6%; P = .043), diabetes (39.4% v 21.6%; P = .001), and obesity (11.6% v 2.0%; P < .0001). Mean follow-up was 35 months. Kaplan-Meier survival rates at 3 and 5 years were 84.4% and 75.9% for patients taking statins and 77.0% and 65.1% for those not taking statins (P = .18). Cox regression analysis selected statins therapy as the only independent negative predictor (odds ratio = 0.55; 95% confidence interval = 0.32-0.95; P = .032) of mortality, while age was an independent positive predictor (odds ratio = 1.05; 95% confidence interval = 1.03-1.08; P < .0001). Vascular access patency was comparable in statin takers and those not taking statins (P = .60). Use of statins might halve the risk of all-cause mortality at 5 years in adult patients with vascular access for chronic dialysis. Statins therapy should be considered in end-stage renal disease populations requiring dialysis access placement. |
Databáze: | OpenAIRE |
Externí odkaz: |